Business
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021
About this update from Kura Oncology, Inc.
[{"type":"text","content":"– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 –\n – Company preparing to initiate a registration-directed trial of tipifarnib in T-cell lymphomas following positive feedback from FDA – – Recommended Phase 2 dose defined for ERK inhibitor KO-947- – Phase 1/2 dose-escalation continues for menin-MLL inhibitor KO-539 – – $236.9 million in cash, cash equivalents and investments provide runway into 2022 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2019 financial results and provided a corporate update. “We entered the new year with three wholly owned, clinical-stage drug candidates and a focus on operational execution across our pipeline,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “The conduct of AIM-HN, our registrational-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinoma (HNSCC), remains our highest priority. We have also taken a number of steps to better position the company for our next phase of growth, including an increasing investment in pre-commercial activities, expansion of our team of medical science liaisons and the appointment of a Chief Commercial Officer. “Meanwhile, our growing body of clinical data in T-cell lymphomas, coupled with positive regulatory feedback and the high unmet need for these patients, support our efforts to expand the development of tipifarnib beyond our initial focus in HRAS mutant solid tumors,” Dr. Wilson continued. “And we continue to make progress with our emerging drug candidates, KO-947 and KO-539, each with the potential to address genetically defined populations of cancer patients. We believe we are well positioned to advance each of our programs to meaningful inflection points, and we look forward to providing updates on our progress in the year ahead.” Recent Highlights Strengthened leadership team to support pre-commercial efforts – In January 2020, Kura appointed Kirsten Flowers to the newly created position of Chief Comme...